Open Calls
There are currently no open calls available.
Upcoming Calls
-
Pre-announcement – EP PerMed Joint Transnational Call (JTC) 2027
The European Partnership for Personalised Medicine (EP PerMed) is launching the Joint Transnational Call 2027 for Cell and Gene Therapy for Personalised Medicine (CGT4PM2027).
Closed Calls
-
Networking Support Call (NSC) 2025
EP PerMed’s Networking Support Call 2025 (NSC2025) represents a key instrument for fostering collaboration, knowledge exchange, and community building in personalised medicine (PM) across Europe and beyond. With a total investment of €389,000, EP PerMed will fund 13 networking events with a diverse portfolio spanning multiple health categories and research domains.
-
Fast Track Validation Programme 2026
The EP PerMed Fast Track Programme 2026 offers targeted support to accelerate the validation and adoption of innovative personalised medicine solutions. The programme helps early-stage innovations progress by at least one Technology Readiness Level through dedicated validation studies carried out together with specialised European validation centres.
-
EP PerMed Joint Transnational Call (JTC) 2026
The Joint Transnational Call (JTC) 2026 “Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases” (acronym: CARMEN2026), co-funded by the European Union, will fund multinational, innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe and beyond in this field.
-
Twinning Call 2026
Six high-quality projects have been selected for funding under the EP PerMed Twinning Call 2026, an initiative designed to accelerate the implementation of personalised medicine approaches across Europe through the transfer of knowledge, expertise, and proven practices between healthcare organisations.
-
Fast Track Validation Programme – Call Announcement
The Call is closed! The EP PerMed Fast Track Call closed in June 2025. Call statistics are available here. Introduction Personalised Medicine (PM) represents a paradigm shift from a “one size fits all” approach to an optimised strategy for the prevention, diagnosis and treatment of disease for each individual, based on their unique characteristics, including…
-
Research, Innovation and Technology Call for Proposals (RITC) 2026
EP PerMed has launched its first research, innovation and technology call (RITC2026) for proposals on “Test and Demonstration of Multimodal Data Approaches for Personalised Medicine”, acronym “MultiPMData2026”. In total, 19 funding organisations participate in this call with an available budget of over 14.8 Mio. € (approx.).
-
EP PerMed Joint Transnational Call (JTC) 2025
EP PerMed has launched its second joint transnational call (JTC2025) for proposals on “Pharmacogenomic strategies for personalised medicine approaches (PGxPM2025)”. In total, 35 funding organisations participate in this call with an available budget of over 36.5 Mio. € (approx.).
-
Education Call: Guide to Personalised Medicine for Healthcare Professionals
Six outstanding projects have been selected for funding under the EP PerMed Education Call 2025. Launched in June 2025, the Education Call supports the creation of educational content aimed at equipping healthcare professionals with the knowledge, skills, and competencies needed to integrate personalised medicine into their daily practice.
-
Venture Creator
Introduction Personalised Medicine (PM) represents a paradigm shift from a “one size fits all” approach to an optimised strategy for the prevention, diagnosis and treatment of disease for each individual, based on their unique characteristics, including biological features (e.g., phenotype, endotype, genotype), as well as lifestyle and environmental factors. Accordingly, PM puts the patient at…
-
Fast Track Validation Programme 2025
Eight outstanding projects were selected for the EP PerMed Fast Track Validation Programme, an initiative designed to accelerate the development, validation, and adoption of innovative personalised medicine (PM) solutions across Europe.